Aggregate Anaphylaxis and Carboxypeptidase N
Bradykinin (BK) is widely believed to play a role in the pathogenesis of anaphylaxis. To help clarify any such roles, we examined for effects of inhibitors of kininase II (angiotensin converting enzyme, ACE) and “kininase I” (carboxypeptidase N, CPN), on the early course of egg albumin-induced aggregate anaphylaxis in anesthetized guinea pigs. In this model, pulmonary and systemic arterial blood pressure (BP) rise (unless pulmonary fibrillation occurs), lung wgt increases by ~ 60% and pulmonary microvessels are occluded by cell-rich thrombi, all within 5 min of i. v. antigen. The 30 min mortality rate is ~ 2%. ACE inhibitors (BPP9a, Captopril and MK 422; doses up to 140 μmol/kg) do not make anaphylaxis more nor less severe in terms discernible by changes in BP, lung wgt, EKG or intravascular coagulation. In marked contrast, an inhibitor of CPN (2-mercaptomethyl-3-guanidinoethylthiopropionic acid, 2-MGP; 8–16 μmol/kg) increases the 30 min mortality rate to 94% and lung wgt to 180% of control. The animals die in ventricular fibrillation. Given the enormous BK potentiating effects of BPP9a, Captopril and MK 422, it seems likely that little if any BK is formed in the early min of anaphylaxis. 2-MGP does not potentiate BP effects of BK but markedly potentiates effects of C3a anaphylatoxin. Thus, our data support the views that 1) BK is neither a primary nor secondary mediator of aggregate anaphylaxis, and 2) the adverse effects of 2-MGP are best explained in terms of preservation of anaphylatoxins and not in terms of preservation of kinins.
KeywordsAngiotensin Converting Enzyme Ventricular Fibrillation Antigenic Challenge Insufflation Pressure Chart Speed
Unable to display preview. Download preview PDF.
- 4.P. J. Piper, Anaphylaxis and the release of active substances in the lungs, Pharmac. Ther. B., 3: 75–98 (1977).Google Scholar
- 5.H. H. Newball, R. W. Berninger, R. C. Talamo, and L. M. Lichtenstein, Anaphylactic release of a basophil kallikrein-like activity. I. Purification and characterization, J. Clin. Invest., 64: 457–465 (1979).Google Scholar
- 8.J. W. Ryan and U. S. Ryan, Endothelial surface enzymes and the dynamic processing of plasma substrates, Intern. Rev. Exp. Pathol., 26: 1–43 (1984).Google Scholar
- 9.R. Huey, C. M. Bloor, M. S. Kawahara, and T. E. Hugli, Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects of pulmonary tissue, Amer. J. Pathol., 112: 48–60 (1983).Google Scholar
- 10.J. W. Ryan, Angiotensin I converting enzyme (kininase II) peptidyl- dipeptide hydrolase EC 126.96.36.199, in: “Methods of Enzymatic Analysis,” H. U. Bergmeyer, ed., Verlag Chemie GmbH, Weinheim, Germany, Vol. 5 (1984).Google Scholar
- 13.W. E. Brocklehurst and S. C. Lahiri, The production of bradykinin in anaphylaxis, J. Physiol., 160: 15–16 (1962).Google Scholar
- 14.S. H. Ferreira, A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca, Br. J. Pharmac. Chemother., 24: 163–169 (1965).Google Scholar
- 15.Y. S. Bakhle, Converting enzyme in vitro measurement and properties, in: “Handbook Exp. Pharmac.,” I. H. Page and F. M. Bumpus, eds., Springer-Verlag, New York, Vol. 37 (1974).Google Scholar